Jaguar Health Inc (JAGX)
0.0681
0.00 (0.00%)
USD |
NASDAQ |
Mar 19, 09:56
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 3.456M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -92.11% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.0908 |
Price to Book Value | 2.541 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 25.49 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 100.00% |
Profile
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment. |
URL | http://www.jaguar.health |
Investor Relations URL | https://jaguarhealth.gcs-web.com/ |
HQ State/Province | California |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 27, 2024 (est.) |
Last Earnings Release | Nov. 14, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment. |
URL | http://www.jaguar.health |
Investor Relations URL | https://jaguarhealth.gcs-web.com/ |
HQ State/Province | California |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 27, 2024 (est.) |
Last Earnings Release | Nov. 14, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |